Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2014
Date: 2015-09-17
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, free movement of goods, market approval, medicinal product, withdrawal from the market








C_2015306EN.01002401.xml










17.9.2015   


EN


Official Journal of the European Union


C 306/24





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2014
(2015/C 306/09)

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July–31 December 2014, at their meeting on 20 March 2015:







Annex I



List of new marketing authorisations





Annex II



List of renewed marketing authorisations





Annex III



List of extended marketing authorisations





Annex IV



List of withdrawn marketing authorisations





Annex V



List of suspended marketing authorisations






ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July – 31 December 2014:








EU Number


Product


Country


Date of authorisation




EU/1/09/527


Ribavirin Teva Pharma BV


Liechtenstein


31.12.2014




EU/1/09/585


Rivastigmine 1A Pharma


Liechtenstein


31.10.2014




EU/1/09/591


Multaq


Liechtenstein


31.10.2014




EU/1/09/595


Sildenafil Actavis


Liechtenstein


31.10.2014




EU/1/09/598


Nevirapine Teva


Liechtenstein


31.8.2014




EU/1/09/599


Rivastigmine Sandoz


Liechtenstein


31.8.2014




EU/1/09/600


Zutectra


Liechtenstein


31.10.2014




EU/1/11/688


Cinryze


Liechtenstein


31.12.2014




EU/1/11/705


Vibativ


Iceland


27.10.2014




EU/1/12/772


Zoledronsäure Teva Pharma


Liechtenstein


31.12.2014




EU/1/13/902


Translarna


Iceland


15.8.2014




EU/1/13/902


Translarna


Liechtenstein


31.8.2014




EU/1/13/902


Translarna


Norway


12.8.2014




EU/1/14/917


Ulunar Breezhaler


Iceland


22.7.2014




EU/1/14/931


Mekinist


Iceland


21.7.2014




EU/1/14/931


Mekinist


Liechtenstein


31.8.2014




EU/1/14/931


Mekinist


Norway


14.7.2014




EU/1/14/933


Simbrinza


Liechtenstein


31.8.2014




EU/1/14/933


Simbrinza


Norway


7.8.2014




EU/1/14/933


Simbrinza


Iceland


14.8.2014




EU/1/14/934


Plegridy


Iceland


15.8.2014




EU/1/14/934


Plegridy


Liechtenstein


31.8.2014




EU/1/14/934


Plegridy


Norway


13.8.2014




EU/1/14/935


Envarsus


Iceland


14.8.2014




EU/1/14/935


Envarsus


Liechtenstein


31.8.2014




EU/1/14/935


Envarsus


Norway


13.8.2014




EU/1/14/936


Nuwiq


Iceland


10.10.2014




EU/1/14/936


Nuwiq


Norway


18.8.2014




EU/1/14/937


Gazyvaro


Iceland


14.8.2014




EU/1/14/937


Gazyvaro


Liechtenstein


31.8.2014




EU/1/14/937


Gazyvaro


Norway


13.8.2014




EU/1/14/938


Zydelig


Iceland


25.9.2014




EU/1/14/938


Zydelig


Liechtenstein


31.10.2014




EU/1/14/938


Zydelig


Norway


2.10.2014




EU/1/14/939


Daklinza


Iceland


11.9.2014




EU/1/14/939


Daklinza


Liechtenstein


31.8.2014




EU/1/14/939


Daklinza


Norway


9.9.2014




EU/1/14/940


Triumeq


Iceland


12.9.2014




EU/1/14/940


Triumeq


Liechtenstein


31.10.2014




EU/1/14/940


Triumeq


Norway


10.9.2014




EU/1/14/941


Vizamyl


Iceland


11.9.2014




EU/1/14/941


Vizamyl


Liechtenstein


31.8.2014




EU/1/14/941


Vizamyl


Norway


12.9.2014




EU/1/14/942


Clopidogrel/Acetylsalicylic acid Teva


Iceland


12.9.2014




EU/1/14/942


Clopidogrel/Acetylsalicylic acid Teva


Norway


25.9.2014




EU/1/14/942


Clopidogrel/Acetylsalicylsäure Teva


Liechtenstein


31.10.2014




EU/1/14/943


Velphoro


Iceland


11.9.2014




EU/1/14/943


Velphoro


Liechtenstein


31.8.2014




EU/1/14/943


Velphoro


Norway


18.9.2014




EU/1/14/944


ABASRIA


Iceland


24.9.2014




EU/1/14/944


ABASRIA


Liechtenstein


31.10.2014




EU/1/14/944


ABASRIA


Norway


24.9.2014




EU/1/14/945


IMBRUVICA


Iceland


18.11.2014




EU/1/14/945


IMBRUVICA


Liechtenstein


31.10.2014




EU/1/14/945


IMBRUVICA


Norway


3.11.2014




EU/1/14/946


Accofil


Iceland


26.9.2014




EU/1/14/946


Accofil


Liechtenstein


31.10.2014




EU/1/14/946


Accofil


Norway


14.10.2014




EU/1/14/947


Xultophy


Iceland


25.9.2014




EU/1/14/947


Xultophy


Liechtenstein


31.10.2014




EU/1/14/947


Xultophy


Norway


25.9.2014




EU/1/14/948


Budesonide/Formoterol Teva


Iceland


16.12.2014




EU/1/14/948


Budesonide/Formoterol Teva


Liechtenstein


31.12.2014




EU/1/14/948


Budesonide/Formoterol Teva


Norway


9.12.2014




EU/1/14/949


Vylaer Spiromax


Iceland


12.12.2014




EU/1/14/949


Vylaer Spiromax


Liechtenstein


31.12.2014




EU/1/14/949


Vylaer Spiromax


Norway


9.12.2014




EU/1/14/950


Budesonide/Formoterol Teva Pharma B.V.


Iceland


16.12.2014




EU/1/14/950


Budesonide/Formoterol Teva Pharma B.V.


Liechtenstein


31.12.2014




EU/1/14/950


Budesonide/Formoterol Teva Pharma B.V.


Norway


9.12.2014




EU/1/14/951


Busulfan Fresenius Kabi


Iceland


25.9.2014




EU/1/14/951


Busulfan Fresenius Kabi


Liechtenstein


31.10.2014




EU/1/14/951


Busulfan Fresenius Kabi


Norway


2.10.2014




EU/1/14/954


Vargatef


Iceland


20.12.2014




EU/1/14/954


Vargatef


Liechtenstein


31.12.2014




EU/1/14/954


Vargatef


Norway


1.12.2014




EU/1/14/955


Lymphoseek


Iceland


19.12.2014




EU/1/14/955


Lymphoseek


Liechtenstein


31.12.2014




EU/1/14/955


Lymphoseek


Norway


10.12.2014




EU/1/14/956


Trulicity


Iceland


20.12.2014




EU/1/14/956


Trulicity


Liechtenstein


31.12.2014




EU/1/14/956


Trulicity


Norway


1.12.2014




EU/1/14/958


Harvoni


Iceland


9.12.2014




EU/1/14/958


Harvoni


Liechtenstein


31.12.2014




EU/1/14/958


Harvoni


Norway


3.12.2014




EU/1/14/959


Lynparza


Liechtenstein


31.12.2014




EU/1/14/960


DUAVIVE


Liechtenstein


31.12.2014




EU/1/14/961


Tadalafil Mylan


Iceland


19.12.2014




EU/1/14/961


Tadalafil Mylan


Liechtenstein


31.12.2014




EU/1/14/961


Tadalafil Mylan


Norway


9.12.2014




EU/1/14/962


Moventig


Iceland


20.12.2014




EU/1/14/962


Moventig


Liechtenstein


31.12.2014




EU/1/14/962


Moventig


Norway


12.12.2014




EU/1/14/963


Brimica Genuair


Iceland


19.12.2014




EU/1/14/963


Brimica Genuair


Liechtenstein


31.12.2014




EU/1/14/963


Brimica Genuair


Norway


8.12.2014




EU/1/14/964


Duaklir Genuair


Iceland


19.12.2014




EU/1/14/964


Duaklir Genuair


Liechtenstein


31.12.2014




EU/1/14/964


Duaklir Genuair


Norway


8.12.2014




EU/1/14/965


Ketoconazole HRA


Norway


8.12.2014




EU/1/14/965


Ketoconazole HRA


Iceland


19.12.2014




EU/1/14/965


Ketoconazole HRA


Liechtenstein


31.12.2014




EU/1/14/967


REZOLSTA


Iceland


17.12.2014




EU/1/14/967


REZOLSTA


Liechtenstein


31.12.2014




EU/1/14/967


REZOLSTA


Norway


4.12.2014




EU/1/14/969


Scenesse


Liechtenstein


31.12.2014




EU/1/14/970


Rixubis


Liechtenstein


31.12.2014




EU/1/14/971


Paliperidone Janssen


Iceland


5.12.2014




EU/1/14/971


Paliperidone Janssen


Liechtenstein


31.12.2014




EU/1/14/971


Paliperidone Janssen


Norway


19.12.2014




EU/1/14/972


Duloxetin Lilly


Liechtenstein


31.12.2014




EU/1/14/972


Duloxetine Lilly


Norway


17.12.2014




EU/2/09/101


Zolvix


Liechtenstein


31.12.2014




EU/2/13/150


Oncept IL-2


Norway


26.9.2014




EU/2/14/163


Versican Plus DHPPi/L4R


Norway


10.7.2014




EU/2/14/164


Versican Plus DHPPi/L4


Norway


21.7.2014




EU/2/14/165


Vectra Felis


Norway


10.7.2014




EU/2/14/166


ERYSENG


Iceland


21.7.2014




EU/2/14/166


Eryseng


Norway


5.8.2014




EU/2/14/166


ERYSENG


Liechtenstein


31.8.2014




EU/2/14/167


ERYSENG PARVO


Iceland


12.8.2014




EU/2/14/167


Eryseng Parvo


Norway


5.8.2014




EU/2/14/167


ERYSENG PARVO


Liechtenstein


31.8.2014




EU/2/14/168


Versican Plus Pi


Iceland


21.7.2014




EU/2/14/168


Versican Plus Pi


Liechtenstein


31.8.2014




EU/2/14/168


Versican Plus Pi


Norway


5.8.2014




EU/2/14/169


Versican Plus DHPPi


Iceland


21.7.2014




EU/2/14/169


Versican Plus DHPPi


Liechtenstein


31.8.2014




EU/2/14/169


Versican Plus DHPPi


Norway


5.8.2014




EU/2/14/170


OSURNIA


Iceland


2.9.2014




EU/2/14/170


Osurnia


Liechtenstein


31.8.2014




EU/2/14/170


Osurnia


Norway


22.9.2014




EU/2/14/171


Versican Plus L4


Iceland


2.9.2014




EU/2/14/171


Versican Plus L4


Liechtenstein


31.8.2014




EU/2/14/171


Versican Plus L4


Norway


11.11.2014




EU/2/14/172


Versican Plus Pi/L4


Iceland


2.9.2014




EU/2/14/172


Versican Plus Pi/L4


Liechtenstein


31.8.2014




EU/2/14/172


Versican Plus Pi/L4


Norway


11.11.2014




EU/2/14/173


Versican Plus Pi/L4R


Norway


11.11.2014




EU/2/14/173


Versican Plus Pi/L4R


Iceland


31.7.2014




EU/2/14/174


Nobilis IB Primo QX


Iceland


24.9.2014




EU/2/14/174


Nobilis IB Primo QX


Liechtenstein


31.10.2014




EU/2/14/174


Nobilis IB Primo QX


Norway


11.11.2014




EU/2/14/175


Porcilis PCV M Hyo


Norway


15.12.2014




EU/2/14/175


Porcilis PCV M Hyo


Iceland


4.12.2014




EU/2/14/175


Porcilis PCV M Hyo


Liechtenstein


31.12.2014




EU/2/14/176


Bovela


Liechtenstein


31.12.2014







ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July – 31 December 2014:








EU Number


Product


Country


Date of authorisation




EU/1/04/287


Osseor


Iceland


16.9.2014




EU/1/04/288


Protelos


Iceland


16.9.2014




EU/1/04/289


Angiox


Iceland


18.7.2014




EU/1/04/289


Angiox


Norway


8.7.2014




EU/1/04/295


Xagrid


Liechtenstein


31.8.2014




EU/1/04/295


Xagrid


Iceland


14.8.2014




EU/1/04/295


Xagrid


Norway


7.8.2014




EU/1/04/298


Kivexa


Liechtenstein


31.12.2014




EU/1/04/298


Kivexa


Iceland


10.12.2014




EU/1/04/298


Kivexa


Norway


17.12.2014




EU/1/04/299


Fendrix


Liechtenstein


31.12.2014




EU/1/04/299


Fendrix


Iceland


9.12.2014




EU/1/04/299


Fendrix


Norway


4.12.2014




EU/1/04/300


Avastin


Liechtenstein


31.12.2014




EU/1/04/300


Avastin


Iceland


12.12.2014




EU/1/04/300


Avastin


Norway


28.11.2014




EU/1/04/302


Prialt


Liechtenstein


31.10.2014




EU/1/04/302


Prialt


Iceland


24.9.2014




EU/1/04/302


Prialt


Norway


26.9.2014




EU/1/09/511


Conbriza


Iceland


16.9.2014




EU/1/09/530


Repaglinide Teva


Iceland


16.7.2014




EU/1/09/530


Repaglinide Teva


Norway


1.7.2014




EU/1/09/539


Samsca


Iceland


18.7.2014




EU/1/09/539


Samsca


Norway


1.7.2014




EU/1/09/545


Onglyza


Liechtenstein


31.8.2014




EU/1/09/545


Onglyza


Iceland


14.8.2014




EU/1/09/545


Onglyza


Norway


25.8.2014




EU/1/09/546


Simponi


Iceland


18.7.2014




EU/1/09/546


Simponi


Norway


10.7.2014




EU/1/09/550


Javlor


Iceland


22.7.2014




EU/1/09/552


Topotecan Teva


Iceland


18.7.2014




EU/1/09/552


Topotecan Teva


Norway


10.7.2014




EU/1/09/555


Clopidogrel TAD


Iceland


22.7.2014




EU/1/09/555


Clopidogrel TAD


Norway


1.7.2014




EU/1/09/559


Clopidogrel Mylan


Norway


1.7.2014




EU/1/09/560


Clopidogrel DURA


Norway


1.7.2014




EU/1/09/562


Clopidogrel Krka d.d.


Iceland


22.7.2014




EU/1/09/562


Clopidogrel Krka d.d.


Norway


1.7.2014




EU/1/09/563


ChondroCelect


Liechtenstein


31.8.2014




EU/1/09/563


ChondroCelect


Iceland


9.9.2014




EU/1/09/563


ChondroCelect


Norway


10.9.2014




EU/1/09/564


Ilaris


Iceland


18.7.2014




EU/1/09/564


Ilaris


Norway


10.7.2014




EU/1/09/565


Biopoin


Liechtenstein


31.10.2014




EU/1/09/565


Biopoin


Iceland


10.9.2014




EU/1/09/565


Biopoin


Norway


8.9.2014




EU/1/09/566


Lamivudine Teva


Liechtenstein


31.10.2014




EU/1/09/566


Lamivudine Teva


Iceland


23.9.2014




EU/1/09/566


Lamivudine Teva


Norway


9.10.2014




EU/1/09/568


Clopidogrel Apotex


Liechtenstein


31.10.2014




EU/1/09/568


Clopidogrel Apotex


Iceland


25.9.2014




EU/1/09/568


Clopidogrel Apotex


Norway


29.9.2014




EU/1/09/569


Exforge HCT


Liechtenstein


31.8.2014




EU/1/09/569


Exforge HCT


Iceland


18.7.2014




EU/1/09/569


Exforge HCT


Norway


29.7.2014




EU/1/09/572


Vantavo


Liechtenstein


31.10.2014




EU/1/09/572


Vantavo


Iceland


25.9.2014




EU/1/09/572


Vantavo


Norway


26.9.2014




EU/1/09/573


Eporatio


Liechtenstein


31.10.2014




EU/1/09/573


Eporatio


Iceland


24.9.2014




EU/1/09/573


Eporatio


Norway


29.9.2014




EU/1/09/574


Dafiro HCT


Liechtenstein


31.8.2014




EU/1/09/574


Dafiro HCT


Iceland


22.7.2014




EU/1/09/574


Dafiro HCT


Norway


4.8.2014




EU/1/09/575


Copalia HCT


Liechtenstein


31.8.2014




EU/1/09/575


Copalia HCT


Iceland


22.7.2014




EU/1/09/575


Copalia HCT


Norway


4.8.2014




EU/1/09/576


Irbesartan Teva


Liechtenstein


31.8.2014




EU/1/09/576


Irbesartan Teva


Iceland


13.8.2014




EU/1/09/576


Irbesartan Teva


Norway


4.8.2014




EU/1/09/577


Foclivia


Liechtenstein


31.8.2014




EU/1/09/577


Foclivia


Iceland


21.7.2014




EU/1/09/577


Foclivia


Norway


29.7.2014




EU/1/09/578


Adjupanrix


Liechtenstein


31.8.2014




EU/1/09/578


Adjupanrix


Iceland


14.8.2014




EU/1/09/578


Adjupanrix


Norway


13.8.2014




EU/1/09/579


Repaglinide Krka


Liechtenstein


31.10.2014




EU/1/09/579


Repaglinide Krka


Iceland


10.9.2014




EU/1/09/579


Repaglinide Krka


Norway


9.9.2014




EU/1/09/580


Enyglid


Liechtenstein


31.8.2014




EU/1/09/580


Enyglid


Iceland


9.9.2014




EU/1/09/580


Enyglid


Norway


10.9.2014




EU/1/09/581


Resolor


Norway


1.7.2014




EU/1/09/583


Irbesartan/Hydrochlorothiazid


Liechtenstein


31.12.2014




EU/1/09/583


Irbesartan/Hydrochlorothiazide Teva


Iceland


9.12.2014




EU/1/09/583


Irbesartan/Hydrochlorotiazide Teva


Norway


27.11.2014




EU/1/09/584


Sildenafil Teva


Liechtenstein


31.10.2014




EU/1/09/584


Sildenafil Teva


Iceland


23.9.2014




EU/1/09/584


Sildenafil Teva


Norway


2.10.2014




EU/1/09/585


Rivastigmine 1A Pharma


Iceland


9.9.2014




EU/1/09/585


Rivastigmine 1A Pharma


Norway


10.9.2014




EU/1/09/586


Oslif Breezhaler


Liechtenstein


31.10.2014




EU/1/09/586


Oslif Breezhaler


Iceland


25.9.2014




EU/1/09/586


Oslif Breezhaler


Norway


14.10.2014




EU/1/09/587


Olanzapine Glenmark


Liechtenstein


31.8.2014




EU/1/09/587


Olanzapine Glenmark


Iceland


9.9.2014




EU/1/09/587


Olanzapine Glenmark


Norway


10.9.2014




EU/1/09/588


Olanzapine Glenmark Europe


Liechtenstein


31.8.2014




EU/1/09/588


Olanzapine Glenmark Europe


Iceland


9.9.2014




EU/1/09/588


Olanzapine Glenmark Europe


Norway


10.9.2014




EU/1/09/589


Rivastigmine HEXAL


Liechtenstein


31.8.2014




EU/1/09/589


Rivastigmine HEXAL


Iceland


13.8.2014




EU/1/09/589


Rivastigmine Hexal


Norway


13.8.2014




EU/1/09/590


Prevenar 13


Liechtenstein


31.12.2014




EU/1/09/590


Prevenar 13


Iceland


10.10.2014




EU/1/09/590


Prevenar 13


Norway


15.10.2014




EU/1/09/591


Multaq


Norway


29.9.2014




EU/1/09/591


Multaq


Iceland


26.9.2014




EU/1/09/592


Olazax Disperzi


Liechtenstein


31.8.2014




EU/1/09/592


Olazax Disperzi


Iceland


4.9.2014




EU/1/09/592


Olazax Disperzi


Norway


27.8.2014




EU/1/09/593


Onbrez Breezhaler


Liechtenstein


31.10.2014




EU/1/09/593


Onbrez Breezhaler


Iceland


25.9.2014




EU/1/09/593


Onbrez Breezhaler


Norway


14.10.2014




EU/1/09/594


Hirobrez Breezhaler


Norway


14.10.2014




EU/1/09/594


Hirobriz Breezhaler


Liechtenstein


31.10.2014




EU/1/09/594


Hirobriz Breezhaler


Iceland


25.9.2014




EU/1/09/595


Sildenafil Actavis


Iceland


23.9.2014




EU/1/09/595


Sildenafil Actavis


Norway


1.10.2014




EU/1/09/596


Lamivudine Teva Pharma B.V.


Liechtenstein


31.10.2014




EU/1/09/596


Lamivudine Teva Pharma B.V.


Iceland


23.9.2014




EU/1/09/596


Lamivudine Teva Pharma B.V.


Norway


9.10.2014




EU/1/09/597


Olazax


Iceland


9.9.2014




EU/1/09/597


Olazax


Norway


10.9.2014




EU/1/09/598


Nevirapine Teva


Iceland


10.9.2014




EU/1/09/598


Nevirapine Teva


Norway


9.9.2014




EU/1/09/599


Rivastigmine Sandoz


Iceland


13.8.2014




EU/1/09/599


Rivastigmine Sandoz


Norway


13.8.2014




EU/1/09/600


Zutectra


Iceland


24.9.2014




EU/1/09/600


Zutectra


Norway


15.10.2014




EU/1/09/601


Firdapse


Norway


18.12.2014




EU/1/09/602


Scintimun


Liechtenstein


31.8.2014




EU/1/09/602


Scintimun


Iceland


10.9.2014




EU/1/09/602


Scintimun


Norway


18.9.2014




EU/1/09/603


Sildenafil ratiopharm


Liechtenstein


31.10.2014




EU/1/09/603


Sildenafil ratiopharm


Iceland


23.9.2014




EU/1/09/603


Sildenafil ratiopharm


Norway


2.10.2014




EU/1/09/604


Leflunomide Winthrop


Liechtenstein


31.12.2014




EU/1/09/604


Leflunomide Winthrop


Iceland


12.12.2014




EU/1/09/604


Leflunomide Winthrop


Norway


28.11.2014




EU/1/09/605


Temomedac


Liechtenstein


31.8.2014




EU/1/09/605


Temomedac


Iceland


13.8.2014




EU/1/09/605


Temomedac


Norway


7.8.2014




EU/1/09/606


Temozolomide Teva


Liechtenstein


31.10.2014




EU/1/09/606


Temozolomide Teva


Iceland


10.9.2014




EU/1/09/606


Temozolomide Teva


Norway


12.9.2014




EU/1/09/607


Silodyx


Liechtenstein


31.10.2014




EU/1/09/607


Silodyx


Iceland


25.9.2014




EU/1/09/607


Silodyx


Norway


15.10.2014




EU/1/09/608


Urorec


Liechtenstein


31.10.2014




EU/1/09/608


Urorec


Iceland


25.9.2014




EU/1/09/608


Urorec


Norway


15.10.2014




EU/1/09/609


Elonva


Liechtenstein


31.8.2014




EU/1/09/609


Elonva


Iceland


10.9.2014




EU/1/09/609


Elonva


Norway


8.9.2014




EU/1/09/611


Docetaxel Teva


Liechtenstein


31.8.2014




EU/1/09/611


Docetaxel Teva


Iceland


12.8.2014




EU/1/09/611


Docetaxel Teva


Norway


6.8.2014




EU/1/10/614


Menveo


Liechtenstein


31.12.2014




EU/1/10/614


Menveo


Iceland


20.12.2014




EU/1/10/614


Menveo


Norway


12.12.2014




EU/1/10/616


Temozolomide HEXAL


Liechtenstein


31.12.2014




EU/1/10/616


Temozolomide Hexal


Iceland


12.12.2014




EU/1/10/616


Temozolomide Hexal


Norway


26.11.2014




EU/1/10/617


Temozolomid Sandoz


Liechtenstein


31.12.2014




EU/1/10/617


Temozolomide Sandoz


Iceland


16.12.2014




EU/1/10/617


Temozolomide Sandoz


Norway


28.11.2014




EU/1/10/619


DuoPlavin


Liechtenstein


31.12.2014




EU/1/10/619


DuoPlavin


Iceland


18.12.2014




EU/1/10/619


DuoPlavin


Norway


3.12.2014




EU/1/10/620


Ristfor


Liechtenstein


31.12.2014




EU/1/10/621


Ristaben


Liechtenstein


31.12.2014




EU/1/10/622


Tepadina


Liechtenstein


31.12.2014




EU/1/10/622


Tepadina


Iceland


10.12.2014




EU/1/10/622


Tepadina


Norway


28.11.2014




EU/1/10/623


DuoCover


Liechtenstein


31.12.2014




EU/1/10/623


DuoCover


Iceland


18.12.2014




EU/1/10/623


DuoCover


Norway


3.12.2014




EU/1/11/710


Votubia


Liechtenstein


31.8.2014




EU/1/11/710


Votubia


Iceland


12.8.2014




EU/1/11/710


Votubia


Norway


7.8.2014




EU/1/12/793


XALKORI


Liechtenstein


31.8.2014




EU/1/12/793


XALKORI


Iceland


10.9.2014




EU/1/12/793


XALKORI


Norway


5.9.2014




EU/1/12/794


ADCETRIS


Liechtenstein


31.8.2014




EU/1/12/794


ADCETRIS


Iceland


10.9.2014




EU/1/12/794


ADCETRIS


Norway


5.9.2014




EU/1/13/848


Erivedge


Liechtenstein


31.8.2014




EU/1/13/848


Erivedge


Iceland


17.7.2014




EU/1/13/848


Erivedge


Norway


5.8.2014




EU/1/97/044


Tasmar


Liechtenstein


31.8.2014




EU/1/97/044


Tasmar


Iceland


13.8.2014




EU/1/97/044


Tasmar


Norway


13.8.2014




EU/1/99/114


Zeffix


Iceland


18.7.2014




EU/1/99/114


Zeffix


Norway


9.7.2014




EU/1/99/123


Renagel


Liechtenstein


31.12.2014




EU/1/99/123


Renagel


Iceland


17.12.2014




EU/1/99/123


Renagel


Norway


10.12.2014




EU/2/04/043


Equilis StrepE


Norway


10.7.2014




EU/2/04/044


Aivlosin


Liechtenstein


31.10.2014




EU/2/04/044


Aivlosin


Iceland


24.9.2014




EU/2/04/044


Aivlosin


Norway


11.11.2014




EU/2/08/086


Equip WNV


Norway


12.11.2014




EU/2/08/087


Masivet


Norway


11.11.2014




EU/2/09/094


BTVPUR AlSap 8


Norway


21.7.2014




EU/2/09/095


Improvac


Norway


11.11.2014




EU/2/09/096


Leucogen


Norway


9.10.2014




EU/2/09/097


Leucofeligen FeLV/RCP


Norway


9.10.2014




EU/2/09/099


Suvaxyn PCV


Norway


21.7.2014




EU/2/09/100


Palladia


Norway


11.11.2014




EU/2/09/100


Palladia


Liechtenstein


31.8.2014




EU/2/09/100


Palladia


Iceland


15.8.2014




EU/2/09/101


Zolvix


Iceland


4.12.2014




EU/2/09/101


Zolvix


Norway


17.12.2014




EU/2/09/102


Gripovac 3


Norway


17.12.2014




EU/2/09/102


Gripovac 3


Liechtenstein


31.12.2014




EU/2/09/102


Gripovac 3


Iceland


20.12.2014




EU/2/09/103


Respiporc Flu3


Liechtenstein


31.12.2014




EU/2/09/103


RESPIPORC FLU3


Iceland


20.12.2014




EU/2/09/104


Zulvac 8 Ovis


Liechtenstein


31.12.2014




EU/2/09/104


Zulvac 8 Ovis


Iceland


4.12.2014




EU/2/09/105


Zulvac 8 Bovis


Norway


15.12.2014




EU/2/09/105


Zulvac 8 Bovis


Liechtenstein


31.12.2014




EU/2/09/105


Zulvac 8 Bovis


Iceland


4.12.2014







ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July – 31 December 2014:








EU Number


Product


Country


Date of authorisation




EU/1/01/195/028-029


Liprolog KwikPen


Norway


20.10.2014




EU/1/03/255/009-010


Ventavis


Iceland


14.8.2014




EU/1/03/255/009-010


Ventavis


Norway


7.8.2014




EU/1/05/320/004


Noxafil


Iceland


10.10.2014




EU/1/05/320/004


Noxafil


Norway


15.10.2014




EU/1/07/436/005


Isentress


Iceland


11.9.2014




EU/1/07/436/005


Isentress


Norway


10.9.2014




EU/1/12/753/013-017


Signifor


Iceland


19.12.2014




EU/1/12/753/013-017


Signifor


Norway


3.12.2014




EU/1/12/771/007-009


Zoledronic acid Teva


Norway


28.10.2014




EU/1/12/773/013-016


Jakavi


Iceland


28.10.2014




EU/1/12/773/013-016


Jakavi


Norway


15.10.2014




EU/1/96/007/039-042


Humalog KwikPen


Norway


20.10.2014




EU/1/99/117/003-004


Synagis


Iceland


11.9.2014




EU/1/99/117/003-004


Synagis


Norway


11.9.2014




EU/2/03/041/006-008


Draxxin


Iceland


12.8.2014




EU/2/03/041/006-008


Draxxin


Norway


18.7.2014




EU/2/11/135/002-003


Panacur AquaSol


Norway


17.12.2014




EU/2/11/135/002-003


Panacur AquaSol


Iceland


15.8.2014







ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July – 31 December 2014:








EU Number


Product


Country


Date of withdrawal




EU/1/06/339


Preotact


Iceland


12.8.2014




EU/1/06/339


Preotact


Norway


13.8.2014




EU/1/07/426


Olanzapine Cipla


Liechtenstein


31.8.2014




EU/1/07/426


Olanzapine Cipla


Iceland


22.7.2014




EU/1/08/467


Doribax


Liechtenstein


31.8.2014




EU/1/08/467


Doribax


Iceland


15.8.2014




EU/1/08/467


Doribax


Norway


13.8.2014




EU/1/09/557


Clopidogrel Qualimed


Liechtenstein


31.10.2014




EU/1/09/557


Clopidogrel Qualimed


Iceland


10.9.2014




EU/1/09/557


Clopidogrel Qualimed


Norway


14.10.2014




EU/1/10/649


Clopidogrel Teva Pharma B.V.


Liechtenstein


31.10.2014




EU/1/10/649


Clopidogrel Teva Pharma B.V.


Iceland


19.11.2014




EU/1/10/661


FLUENZ


Liechtenstein


31.12.2014




EU/1/10/661


Fluenz


Iceland


18.11.2014




EU/1/10/661


Fluenz


Norway


17.12.2014




EU/1/10/662


Docetaxel Teva Pharma


Iceland


12.8.2014




EU/1/11/675


Leflunomide Teva


Iceland


12.8.2014




EU/1/11/689


IOA


Liechtenstein


31.8.2014




EU/1/11/689


Ioa


Iceland


2.9.2014




EU/1/11/689


IOA


Norway


16.9.2014




EU/1/11/723


Pioglitazon Krka


Liechtenstein


31.10.2014




EU/1/11/723


Pioglitazone Krka


Iceland


24.9.2014




EU/1/11/735


Ipreziv


Liechtenstein


31.12.2014




EU/1/11/735


Ipreziv


Iceland


19.11.2014




EU/1/11/735


Ipreziv


Norway


17.12.2014




EU/1/11/744


Topotecan Eagle


Liechtenstein


31.10.2014




EU/1/11/744


Topotecan Eagle


Iceland


27.10.2014




EU/1/11/744


Topotecan Eagle


Norway


5.11.2014




EU/1/14/911


Rivastigmine 3M Health Care Ltd.


Liechtenstein


31.8.2014




EU/1/14/911


Rivastigmine 3M Health Care Ltd.


Iceland


4.9.2014




EU/1/14/911


Rivastigmine 3M Health Care Ltd.


Norway


16.9.2014




EU/1/97/037


Vistide


Liechtenstein


31.10.2014




EU/1/97/037


Vistide


Iceland


10.9.2014




EU/1/97/043


Revasc


Liechtenstein


31.8.2014




EU/1/97/043


Revasc


Iceland


14.8.2014




EU/1/97/043


Revasc


Norway


26.8.2014




EU/2/06/058


Flexicam


Iceland


12.8.2014







ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July – 31 December 2014:








EU Number


Product


Country


Date of suspension




EU/1/13/847


MACI


Liechtenstein


31.12.2014




EU/1/13/847


MACI


Iceland


19.12.2014